These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20839930

  • 1. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T.
    Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
    [Abstract] [Full Text] [Related]

  • 2. Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan.
    Kim CO, Cho SK, Oh ES, Park MS, Chung JY.
    J Cardiovasc Pharmacol; 2012 Jul; 60(1):49-54. PubMed ID: 22494992
    [Abstract] [Full Text] [Related]

  • 3. An update on the clinical pharmacokinetics of fexofenadine enantiomers.
    Akamine Y, Miura M.
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):429-434. PubMed ID: 29635947
    [Abstract] [Full Text] [Related]

  • 4. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS.
    Cancer; 2007 Jul 01; 110(1):138-47. PubMed ID: 17534875
    [Abstract] [Full Text] [Related]

  • 5. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V, Svenningsen K, Knudsen LA, Hansen AK, Holmskov U, Stensballe A, Vogel U.
    World J Gastroenterol; 2015 Nov 07; 21(41):11862-76. PubMed ID: 26557010
    [Abstract] [Full Text] [Related]

  • 6. [Determinants of the stereoselective pharmacokinetics of fexofenadine].
    Akamine Y.
    Yakugaku Zasshi; 2015 Nov 07; 135(3):473-81. PubMed ID: 25759055
    [Abstract] [Full Text] [Related]

  • 7. Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
    Vanhove T, Bouillon T, de Loor H, Annaert P, Kuypers D.
    Clin Pharmacol Ther; 2017 Dec 07; 102(6):989-996. PubMed ID: 28437851
    [Abstract] [Full Text] [Related]

  • 8. Telmisartan pharmacokinetics in Japanese renal transplant recipients.
    Miura M, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T.
    Clin Chim Acta; 2009 Jan 07; 399(1-2):83-7. PubMed ID: 18838068
    [Abstract] [Full Text] [Related]

  • 9. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
    Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T.
    Ther Drug Monit; 2008 Oct 07; 30(5):559-64. PubMed ID: 18695635
    [Abstract] [Full Text] [Related]

  • 10. Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium.
    Martino A, Campa D, Buda G, Sainz J, García-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M, Ríos R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F, Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F, Rossi AM.
    Leukemia; 2012 Jun 07; 26(6):1419-22. PubMed ID: 22182917
    [No Abstract] [Full Text] [Related]

  • 11. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients.
    Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T.
    Eur J Clin Pharmacol; 2007 Dec 07; 63(12):1161-9. PubMed ID: 17906856
    [Abstract] [Full Text] [Related]

  • 12. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
    Campa D, Müller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A.
    Int J Cancer; 2012 Dec 15; 131(12):2920-8. PubMed ID: 22473764
    [Abstract] [Full Text] [Related]

  • 13. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers.
    Akamine Y, Miura M, Yasui-Furukori N, Ieiri I, Uno T.
    J Clin Pharm Ther; 2015 Feb 15; 40(1):98-103. PubMed ID: 25263393
    [Abstract] [Full Text] [Related]

  • 14. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy.
    Kim DW, Lee SK, Chu K, Jang IJ, Yu KS, Cho JY, Kim SJ.
    Epilepsy Res; 2009 Mar 15; 84(1):86-90. PubMed ID: 19167193
    [Abstract] [Full Text] [Related]

  • 15. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
    Neumanova Z, Cerveny L, Ceckova M, Staud F.
    AIDS; 2014 Jan 02; 28(1):9-17. PubMed ID: 24413260
    [Abstract] [Full Text] [Related]

  • 16. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
    Bruhn O, Cascorbi I.
    Expert Opin Drug Metab Toxicol; 2014 Oct 02; 10(10):1337-54. PubMed ID: 25162314
    [Abstract] [Full Text] [Related]

  • 17. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y, Hamada A, Nakashima R, Yuki M, Hirayama C, Kawaguchi T, Saito H.
    Ther Drug Monit; 2011 Apr 02; 33(2):244-50. PubMed ID: 21311410
    [Abstract] [Full Text] [Related]

  • 18. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals.
    Geng F, Jiao Z, Dao YJ, Qiu XY, Ding JJ, Shi XJ, Li ZD, Zhong MK.
    Clin Chim Acta; 2012 Apr 11; 413(7-8):683-90. PubMed ID: 22227166
    [Abstract] [Full Text] [Related]

  • 19. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
    Salphati L, Plise EG, Li G.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):463-8. PubMed ID: 19491037
    [Abstract] [Full Text] [Related]

  • 20. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
    Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG.
    Clin Pharmacol Ther; 2004 Nov 28; 76(5):418-27. PubMed ID: 15536457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.